Status:
COMPLETED
Phase III Study of Gemcitabine Plus a Cytotoxic Agent Versus Two Cytotoxic Agents
Lead Sponsor:
Eli Lilly and Company
Conditions:
Breast Neoplasms
Eligibility:
FEMALE
18+ years
Phase:
PHASE3
Brief Summary
This is a phase III randomized study which compares two different regimens of chemotherapy. The purpose of the study is to determine which of the two regimens will make the tumor smaller or disappear,...
Eligibility Criteria
Inclusion
- Locally advanced and/or metastatic breast cancer.
- Measurable disease
- Previously treated with anthracycline
Exclusion
- Patients with inflammatory breast disease
Key Trial Info
Start Date :
October 1 2002
Trial Type :
INTERVENTIONAL
End Date :
March 1 2007
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT00191438
Start Date
October 1 2002
End Date
March 1 2007
Last Update
May 28 2007
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Saint-Herblain, France, 44805
2
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Heidelberg, Germany, D-69115
3
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Napoli, Italy, 80131
4
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Arnhem, Netherlands, 6815AD